Anisodamine is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is First Affiliated Hospital of Wannan Medical College (1). The most-studied condition is Septic Shock.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
NCT05727163 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic
|
Phase 2 | Recruiting | Sun Yat-sen University | China |
|
Effects of Anisodamine on Sublingual Microcirculation and Vascular Waterfall Phenomenon in Patients With Septic Shock
NCT07657702 · ClinicalTrials.gov ↗ · Septic Shock, Sepsis, Critical Illness
|
Not applicable | Not yet open | First Affiliated Hospital of Wannan Medical College | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| First Affiliated Hospital of Wannan Medical College | 1 |
| Sun Yat-sen University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Anisodamine as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
First Affiliated Hospital of Wannan Medical College (1) and Sun Yat-sen University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Anisodamine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Anisodamine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Anisodamine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.